Investigational Drug Details
| Drug ID: | D484 |
| Drug Name: | Acipimox |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB09055 |
| DrugBank Description: | Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout. |
| PubChem ID: | 5310993 |
| CasNo: | 51037-30-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC1=[N+]([O-])C=C(N=C1)C(O)=O |
| Structure: |
|
| InChiKey: | DJQOOSBJCLSSEY-UHFFFAOYSA-N |
| Molecular Weight: | 154.125 |
| DrugBank Targets: | |
| DrugBank MoA: | Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. |
| DrugBank Pharmacology: | |
| DrugBank Indication: | Used in the treatment of hyperlipidemias (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood). |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|